China Resources Pharmaceutical Group Ltd. (640) Stock Price & Analysis
640 Stock Chart & Stats
- Day’s Range
- EUR 0.52 - EUR 0.52
- 52-Week Range
- EUR 0.45 - EUR 0.71
- Previous Close
- EUR 0.51
- Volume
- 0
- Average Volume (3M)
- 3,543
- Market Cap
- EUR 3.31B
- Enterprise Value
- EUR 173.67B
- Total Cash (Recent Filing)
- EUR 44.03B
- Total Debt (Recent Filing)
- EUR 114.17B
- Price to Earnings (P/E)
- 6.2
- Beta
- 0.32
- Next Earnings
- N/A
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- 4.96%
Bulls Say, Bears Say
Bulls Say
Integrated Business Model
Vertical integration across distribution, retail and manufacturing creates durable revenue diversification and supply‑chain control. This reduces dependence on a single channel, enables cross‑selling and inventory efficiency, supporting stable cash flow and resilience over months.
Strong Cash Generation
Consistently strong operating and free cash flow relative to earnings improves financial flexibility for capex, dividends and debt servicing. Reliable cash conversion supports strategic investments and cushions the business against cyclical pressures over the medium term.
Steady Revenue And Operating Profitability
Return to mid‑single‑digit revenue growth and stable operating margins indicate underlying demand and operational stability. Consistent top‑line expansion plus modest operating margin improvement supports sustainable earnings power and reinvestment capacity over 2–6 months.
Bears Say
Very Thin Net Margins
Net margins near 1–1.5% leave little room for error: small cost increases or pricing pressure materially reduce profits. Limited bottom‑line leverage constrains retained earnings, weakens return sensitivity, and hampers long‑term capacity to build equity organically.
Rising Leverage
Material rise in leverage increases interest burden and financial risk, reducing flexibility for M&A or capital spending. Elevated debt levels amplify downside in an adverse environment and make the company more sensitive to credit conditions over the medium term.
Low Debt Coverage By Cash Flow
Operating cash flow covers a tiny fraction of total debt, limiting the company’s ability to deleverage quickly. This structural cash‑coverage gap constrains capital allocation choices and raises refinancing or liquidity risk if market conditions tighten.
China Resources Pharmaceutical Group Ltd. News
640 FAQ
What was China Resources Pharmaceutical Group Ltd.’s price range in the past 12 months?
What is China Resources Pharmaceutical Group Ltd.’s market cap?
When is China Resources Pharmaceutical Group Ltd.’s upcoming earnings report date?
How were China Resources Pharmaceutical Group Ltd.’s earnings last quarter?
Is China Resources Pharmaceutical Group Ltd. overvalued?
Does China Resources Pharmaceutical Group Ltd. pay dividends?
What is China Resources Pharmaceutical Group Ltd.’s EPS estimate?
How many shares outstanding does China Resources Pharmaceutical Group Ltd. have?
What happened to China Resources Pharmaceutical Group Ltd.’s price movement after its last earnings report?
Which hedge fund is a major shareholder of China Resources Pharmaceutical Group Ltd.?
What is the TipRanks Smart Score and how is it calculated?
China Resources Pharmaceutical Group Ltd. Stock Smart Score
Company Description
China Resources Pharmaceutical Group Ltd.
China Resources Pharmaceutical Group Limited, an investment holding company, engages in the manufacture, distribution, and retail of pharmaceutical and other healthcare products in Mainland China and internationally. It operates through four segments: Pharmaceutical Manufacturing, Pharmaceutical Distribution, Pharmaceutical Retail, and Others. The company offers a range of chemical drugs, Chinese medicines, and biological drugs, as well as nutritional and healthcare products for various therapeutic areas, including cardiovascular and cerebrovascular diseases, alimentary tract, endocrine diseases, respiratory diseases, orthopedics, nephrology, rheumatology and immunology, medical nutrition, pediatrics, genitourinary system, dermatological diseases, blood products, therapeutic infusions, antitumor drugs, medicine for cough and cold, anti-infection drugs, and psychoneurosis. It also provides warehousing, logistics, and other value-added pharmaceutical supply chain solutions and related services to pharmaceutical/medical device manufacturers and dispensers, such as hospitals, distributors, and retail pharmacies. In addition, the company is involved in property holding activities, as well as operates retail pharmacies under the Teck Soon Hong brands. It distributes its products under the 999, Dong-E-E-Jiao, Double Crane, Zizhu, Jiangzhong, Boya, and Kun Zhong Yao to hospitals and other medical institutions. The company was formerly known as China Resources Medications Group Limited and changed its name to China Resources Pharmaceutical Group Limited in December 2011. The company was incorporated in 2007 and is based in Wan Chai, Hong Kong. China Resources Pharmaceutical Group Limited is a subsidiary of CRH (Pharmaceutical) Limited.
- Sector
- Healthcare
- Industry
- Medical - Pharmaceuticals
- CEO
- Xiaosong Bai
- Employees
- 84,000
- Website
- www.crpharm.com
- Address
- HK
China Resources Pharmaceutical Group Ltd. (640) Earnings & Revenues
640 Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 15 | 4 | 2 |
| Technical Analysis | 3 | 4 | 2 |
| Moving Averages | 12 | 0 | 0 |